 Postexposure prophylaxis zidovudine suppresses human immunodeficiency virus type infection SCID-hu mice time-dependent manner Occupational exposure human immunodeficiency virus HIV low finite incidence infection health care providers circumstances postexposure administration zidovudine AZT beneficial possibility SCID-hu mouse immunodeficient scid/scid mouse human hematolymphoid organs AZT different times intravenous infection standard dose HIV animals AZT infection animals days suppression animals AZT-sensitive phase data support hypothesis prompt administration AZT efficacious acute HIV infection humans Further studies SCID-hu mouse insight treatment protocols efficacy